Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

The FDA approved a new Pfizer drug for hair loss in teens.

PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

CTP-543 is generally safe for treating alopecia areata.

Antizyme reduces tumor growth and normalizes skin cell development affected by MEK.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Overexpressing PKCepsilon in mice reduces papillomas but increases carcinomas.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Targeting DKK3–CKAP4 can help reverse hair loss in androgenetic alopecia.

Pexidartinib often causes liver issues and fatigue, especially in women.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

K10 may not prevent tumors as previously thought and might increase benign tumor risk.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

The combination treatment showed a higher response rate but no significant survival benefits.

ICP5249 helps hair grow by activating a specific cell pathway.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Dkk4 is necessary for the initial development and arrangement of hair follicles.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

ITK inhibitors may effectively treat alopecia areata.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Cialis and Finasteride could be repurposed to treat aggressive melanoma.